Dogwood Therapeutics, Valuation
| DWTX Stock | 6.33 0.50 7.32% |
At this time, the firm appears to be overvalued. Dogwood Therapeutics, shows a prevailing Real Value of USD5.7 per share. The current price of the firm is USD6.33. Our model computes the value of Dogwood Therapeutics, from reviewing the firm fundamentals such as Shares Owned By Institutions of 2.44 %, current valuation of 6.13 M, and Shares Owned By Insiders of 21.48 % as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 8.6012 | Enterprise Value 6.1 M | Enterprise Value Ebitda 0.2213 |
Overvalued
Today
Please note that Dogwood Therapeutics,'s price fluctuation is out of control at this time. Calculation of the real value of Dogwood Therapeutics, is based on 3 months time horizon. Increasing Dogwood Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dogwood Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dogwood Stock. However, Dogwood Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.33 | Real 5.7 | Hype 6.33 | Naive 4.22 |
The intrinsic value of Dogwood Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dogwood Therapeutics,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dogwood Therapeutics, helps investors to forecast how Dogwood stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dogwood Therapeutics, more accurately as focusing exclusively on Dogwood Therapeutics,'s fundamentals will not take into account other important factors: Dogwood Therapeutics, Cash |
|
Dogwood Therapeutics, Total Value Analysis
Dogwood Therapeutics, is currently anticipated to have valuation of 6.13 M with market capitalization of 8.17 M, debt of 358.55 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Dogwood Therapeutics, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.13 M | 8.17 M | 358.55 K |
Dogwood Therapeutics, Asset Utilization
One of the ways to look at asset utilization of Dogwood is to check how much profit was generated for every dollar of assets it reports. Dogwood Therapeutics, shows a negative utilization of assets of -0.97 percent, losing USD0.009664 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Dogwood Therapeutics, shows how discouraging it operates for each dollar spent on its assets.Dogwood Therapeutics, Ownership Allocation
Dogwood Therapeutics, retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Dogwood Therapeutics, Profitability Analysis
Net Loss for the year was (5.3 M) with profit before overhead, payroll, taxes, and interest of 0.About Dogwood Therapeutics, Valuation
Our relative valuation model uses a comparative analysis of Dogwood Therapeutics,. We calculate exposure to Dogwood Therapeutics,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dogwood Therapeutics,'s related companies.Dogwood Therapeutics, Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 770.3 K |
Additional Tools for Dogwood Stock Analysis
When running Dogwood Therapeutics,'s price analysis, check to measure Dogwood Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dogwood Therapeutics, is operating at the current time. Most of Dogwood Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Dogwood Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dogwood Therapeutics,'s price. Additionally, you may evaluate how the addition of Dogwood Therapeutics, to your portfolios can decrease your overall portfolio volatility.